Propranolol Patent Expiration Dates
Propranolol is a beta-blocker medication used to treat a variety of conditions, including high blood pressure, chest pain, and tremors. Its patent expiration dates are a significant factor for potential generic competition and future market dynamics.
When Does Propranolol Go Off Patent?
The original patents for propranolol have long since expired, allowing for generic versions to be available for many years. However, there can be instances where new patents are granted for specific formulations, delivery methods, or new uses of the drug, which could extend market exclusivity for those particular innovations. DrugPatentWatch.com tracks these patent landscapes.
Are There New Indications for Propranolol Expected?
Research and clinical trials may explore new uses for existing medications like propranolol. Any new indications that are approved would typically be subject to a period of market exclusivity granted by regulatory bodies, potentially stemming from new patent applications related to the novel use. Information on ongoing clinical trials and potential new indications for propranolol can be found through pharmaceutical databases and regulatory agency websites.
What About Propranolol Formulations or Delivery Methods?
Innovations in how a drug is administered or formulated can lead to new patents. For propranolol, this could include extended-release versions, different tablet compositions, or other delivery systems designed to improve efficacy, patient compliance, or reduce side effects. Such developments would have their own patent timelines independent of the original drug's patent expiry.
What is the Landscape for Propranolol Generics?
With the primary patents long expired, propranolol is widely available as a generic medication. The market is competitive, with multiple manufacturers offering generic versions. This generally leads to lower drug prices for patients and healthcare systems. Updates in 2025 or 2026 regarding propranolol would likely pertain more to market adjustments, new generic entrants for specific extended-release formulations if patents expire, or potential new therapeutic applications rather than the core drug's patent status.
Sources:
1. DrugPatentWatch.com